Objective: The paper evaluates the difference in clinical efficacy between the bid-winning generic and original drugs in the centralized procurement of Bortezomib for the treatment of first-visit multiple myeloma based on multicenter real-world data. Methods: Data of patients treated with Bortezomib in the electronic medical record system of five hospitals in Shanghai from January 2017 to June 2024 were collected retrospectively. The first-visit patients were screened out and divided into the generic and original groups according to different medications. Patients’ baseline data of the two groups were corrected by the propensity score matching method. The direct and indirect indexes of therapeutic effect, adverse reactions and residents' affordability were compared between the two groups. Results: There were 215 patients in both the generic and original groups, screened by 1:1 matching of baseline data. There was no significant difference between the two groups after 4 courses of Bortezomib-containing therapy (P>0.05). There was no significant difference in the changes of M protein, plasma cell ratio of myeloma, β2-microglobulin, creatinine, calcium and sFLC-λ between the two groups. The original group had an advantage in protecting renal function (P<0.05), and the centralized procurement group had an advantage in controlling LDH increase (P<0.05). In terms of safety, there was no significant difference in the incidence of lethargy, pain, peripheral neuropathy, rash and allergy between the two groups (P>0.05). However, the incidence of fatigue was higher in the original group (P<0.05). The generic drugs were more affordable. Conclusion: The overall effectiveness and safety of selected drugs in the centralized procurement of Bortezomib are not inferior to the original drugs, and some indicators have their own advantages.
Key words
Bortezomib /
multiple myeloma /
centralized drug procurement /
generic drug /
original drug /
real-world study
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] GODFREY J, BENSON D M JR. The role of natural killer cells in immunity against multiple myeloma[J]. Leuk lymphoma, 2012, 53(9):1666-1676.
[2] MILLER KD, GODING SAUER A, ORTIZ AP, et al.Cancer statistics for Hispanics/Latinos, 2018[J]. CA Cancer J Clin, 2018, 68(6): 425-445.
[3] Ye Z, Chen J, Xuan Z, et al.Subcutaneous Bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis[J]. Drug design development and therapy, 2019, 13: 1707-1716.
[4] SAMALA RENATO V.Palliative care in patients with multiple myeloma[J]. Journal of pain and symptom management, 2019, 58(6):1113-1118.
[5] 伊佳,徐德铎,侯幸赟,等.硼替佐米治疗多发性骨髓瘤的临床综合评价[J].上海医药,2024,45(1):33-38.
[6] 罗巧,王之舟,刘文娜,等.格列美脲集采中选仿制药与原研药临床效果的真实世界研究[J].中国药业,2023,32(24):50-54.
[7] 张焕波,张岳洋,孙珮.加快完善药品和医用耗材集中带量采购制度[J].中国物价,2023(7):68-71.
[8] 李钊,陈盛,周绿林,等.国家组织药品集中带量采购的实践操作问题与优化对策[J].中国卫生经济,41(7):60-64.
[9] 邢玥,刘通,滕雪,等.曲妥珠单抗生物仿制药对比原研药治疗复发或转移性HER-2阳性乳腺癌的药物经济学评价[J].中国药房,2024,35(9):1113-1117.
[10] 郭斯伦,马韶青.美国竞争性仿制药激励制度述评及对我国的启示[J].中国药房,2023,34(13):1562-1566.
[11] HE J, HE D, HAN X, et al.Bortezomib-based regimens for newly diagnosed multiple myeloma in China: a report of 12-year real-world data[J]. Frontiers in pharmacology,2020 (12):561601.
[12] 高欣,解海谊,王慧涵,等.国产与进口硼替佐米治疗多发性骨髓瘤的真实世界疗效、安全性及经济学对比[J].现代肿瘤医学,2022,30(10):1821-1825.
[13] 邓雨琴,毛盼盼,刘璐,等.基于多中心真实世界数据的集采有效性、安全性和经济性评价——以替加环素为例[J]. 中国医疗保险,2024(5),109-115.
[14] PALUMBO A, RAJKUMAR SV,SAN MIGUEL JF,et al.International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J]. Journal of clinical oncology,2014,32(6):587-600.
[15] 卢洁,王宏强,陆风雁.国产硼替佐米对多发性骨髓瘤患者的疗效及对血清sFLC、LDH和ALB的影响[J].现代实用医学,2022,34(8):1036-1038.
[16] 陈园园,李英华,王东梅,等.含小剂量硼替佐米的三药联合方案治疗老年多发性骨髓瘤的临床研究[J].中国医院用药评价与分析, 2022,22(6):697-699.
[17] 国家统计局,2023年居民收入和消费支出情况[EB/OL].(2024-01-17)[2024-07-30].https://www.stats.gov.cn/sj/zxfb/202401/t20240116_1946622.html.
[18] 朱楚玉,孙维阳.常峰.我国罕见病药品价格水平和可负担性研究[J].中国药房,2021,32(8):897-903.
[19] 徐倩,徐斌.上海市口服抗帕金森病药品可负担性评价[J].中国药业,2021,30(223):1-4.
[20] 刘桂娟,公海艳,彭海英. 联合检测血清 LDH、SF、sFLC 在多发性骨髓瘤诊断中的价值[J].检验医学与临床,2023,20(16):2433-2435.
[21] 陈绿云,殷佳慧,杨岚寓,等.SUDOSCAN 检测快速有效评估硼替佐米致周围神经病变[J]. 中国肿瘤临床,2023,50(8):398-402.
